Victoria Cacheux
YOU?
Author Swipe
View article: Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia
Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia Open
View article: 52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY Open
View article: Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study Open
PURPOSE BCR::ABL1 quantification is widely regarded as the standard for monitoring measurable residual disease (MRD) in Philadelphia chromosome–positive (Ph+) ALL. However, recent evidence of BCR::ABL1 multilineage involvement questions th…
View article: Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma Open
Obinutuzumab (O) and rituximab (R) are 2 CD antibodies that have never been compared in a prospective randomized trial of mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LyMa-101 trial, in which newly diagnosed p…
View article: Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study
Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study Open
Purpose. The growing choice of oral anticancer medications (OAMs) delivered in pharmacies puts the patients at the center of their own therapeutic management. Patient satisfaction regarding their pharmaceutical management is particularly i…
View article: Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma
Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma Open
Rituximab maintenance (RM) after autologous stem cell transplantation (ASCT) is standard-of-care for young patients with mantle cell lymphoma (MCL). RM may enhance post-transplantation immune depression and risk of infections. We compared …
View article: Hemophagocytosis by acute myeloid leukemia blasts associated to poor clinical outcomes
Hemophagocytosis by acute myeloid leukemia blasts associated to poor clinical outcomes Open
A 74-year-old man was referred to the university hospital for fatigue, weight loss, and thrombocytopenia. Initial examination revealed maculopapular lesions on his body. Subsequent blood tests showed mild normocytic anemia (12.1 g/dL), thr…
View article: Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma Open
Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly population that has a poor prognosis when treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy. Lenalidomide, which ha…
View article: Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group Open
View article: Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study
Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study Open
Patients undergoing treatment for acute lymphoblastic leukemia (ALL) are at risk for thrombosis, in part due to the use of L-asparaginase (L-ASP). Antithrombin (AT) replacement has been suggested to prevent VTE and thus might increase expo…
View article: S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA‐101 TRIAL ‐ A LYSA TRIAL
S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA‐101 TRIAL ‐ A LYSA TRIAL Open
Background: Achievement of prolonged minimal residual disease (MRD) negativity after both induction and ASCT is a strong independent prognostic marker in mantle cell lymphoma (MCL). A high‐dose aracytine‐ (HA) and salt platinum‐containing …
View article: Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients
Human herpesvirus 6 infection after autologous stem cell transplantation: A multicenter prospective study in adult patients Open
View article: Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with <scp>l</scp>‐asparaginase: The <scp>GRAALL</scp> experience
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with <span>l</span>‐asparaginase: The <span>GRAALL</span> experience Open
Central nervous system (CNS) thrombotic events are a well‐known complication of acute lymphoblastic leukemia (ALL) induction therapy, especially with treatments including l ‐asparaginase ( l ‐ASP). Data on risk factors and clinical evoluti…